Analyst Ratings for ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter, with a total of 3 bullish, 5 somewhat bullish, and 7 indifferent ratings. The average price target for ACADIA Pharmaceuticals over the next 12 months is $32.07, an increase of 15.03% from the previous average price target of $27.88.
October 10, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals received mixed ratings from analysts, with an increased average price target of $32.07.
The mixed ratings from analysts indicate uncertainty about the company's performance. However, the increased average price target suggests a positive outlook, which could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100